RCM
VINC

Radcliffe Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Radcliffe Capital Management’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,617
Closed -$333K – 243
2020
Q2 		$333K Buy
+1,617
New +$320K 0.05% 136

Other funds holding VINC

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Radcliffe Capital Management's VINC Position: Q3 2020 in Review

Radcliffe Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q3 2020, closing a stake of 1,617 shares — an estimated $333K sold.

Radcliffe Capital Management first reported a position in VINC in Q2 2020 and held it in 1 quarter. The position peaked at $333K in Q2 2020. 12 funds tracked by Wall St. Rank hold VINC as of Q3 2020.

  • Radcliffe Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Radcliffe Capital Management sold 1,617 Vincerx Pharma, Inc. Common Stock shares in Q3 2020, an estimated $333K.
  • Radcliffe Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Radcliffe Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $333K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2020.

Based on Radcliffe Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.